# Gabriel Tremblay

> Gabriel Levesque-Tremblay is the CEO and co-founder of HexemBio, a New York and Berkeley biotech building what it calls the first scalable blood stem cell rejuvenation therapy. A synthetic biologist with a PhD from UBC and a postdoc at UC Berkeley, he is a two-time founder and Y Combinator alumnus who earlier co-founded the cultivated-meat startup Orbillion Bio. At HexemBio he turns aged hematopoietic stem cells young again by passing them through a recreated embryonic 'Synthetic Yolk Sac' before returning them by IV. The company closed a $10.4M seed round led by Draper Associates in April 2026 and is targeting first-in-human trials by 2027.

- **Role:** CEO & Co-Founder at HexemBio
- **Organizations:** HexemBio, Orbillion Bio, AIChE, Y Combinator (alumnus)
- **From:** Chicoutimi, Quebec, Canada
- **Nationality:** Canadian-American
- **Education:** PhD, University of British Columbia (UBC), BSc and MSc in Science, University of Quebec in Montreal (UQAM), Postdoctoral research, synthetic biology, UC Berkeley
- **Known for:** Co-founded and leads HexemBio, developer of what it calls the first scalable blood stem cell rejuvenation therapy, Raised a $10.4M seed round led by Draper Associates, with SOSV and Seraphim Space, Two-time founder and Y Combinator alumnus

## Career timeline

- **2021** — Co-founded Orbillion Bio (CTO); the cultivated-meat startup graduated from Y Combinator (W21)
- **2021-2024** — Directed technical affairs at AIChE, helping secure over $100M in grants from NSF, DOE, NIH and DOD and helping establish the Regenerative Engineering Society and CRISPR/Stem Cell Engineering communities
- **2024** — Foundational Synthetic Human Yolk Sac research published in Nature (Ebrahimkhani lab, University of Pittsburgh)
- **2025** — HexemBio won the Crimson Founders Most Innovative Tech Award at the Future 100 Forum / Investopia 2025 in Abu Dhabi; FDA Orphan Drug Designation granted (July 2025)
- **2026** — Completed FDA Pre-IND meeting (Jan); publicly launched HexemBio and closed a $10.4M seed round led by Draper Associates (April)
- **2027** — Targeted first-in-human trials

## Achievements

- Co-founded and leads HexemBio, developer of what it calls the first scalable blood stem cell rejuvenation therapy
- Raised a $10.4M seed round led by Draper Associates, with SOSV and Seraphim Space
- Two-time founder and Y Combinator alumnus
- Co-founded Orbillion Bio, building an AI-biology algorithm to scale low-cost cultivated beef and wagyu
- Won the Crimson Founders Most Innovative Tech Award at Investopia 2025, Abu Dhabi
- While at AIChE, helped secure over $100M in grants from NSF, DOE, NIH and DOD
- Helped establish the Regenerative Engineering Society and CRISPR/Stem Cell Engineering communities

## Latest updates

- **2026-04** — HexemBio publicly launched and closed a $10.4M seed round led by Draper Associates, targeting first-in-human trials in 2027.
- **2026-01** — Completed an FDA Pre-IND meeting for its lead program.
- **2025-07** — Received FDA Orphan Drug Designation.
- **2025-02** — HexemBio won the Crimson Founders Most Innovative Tech Award at Investopia 2025 in Abu Dhabi.

## Links

- Website: https://hexemb.io
- LinkedIn: http://www.linkedin.com/in/gabriellt
- YouTube: https://youtu.be/hTfmDBpl0Ik

---

Profile page: https://yespress.io/gabriel-tremblay
Published by YesPress — https://yespress.io
Last updated: 2026-06-24